Table 2: Joanna Briggs Institute critical appraisal checklist for randomised clinical trials.
Article |
Q1 |
Q2 |
Q3 |
Q4 |
Q5 |
Q6 |
Q7 |
Q8 |
Q9 |
Q10 |
Q11 |
Q12 |
Q13 |
Score |
Cremascoli, et al. [30] |
Y |
Y |
Y |
N |
Y |
Y |
Y |
Y |
N |
Y |
N |
N |
Y |
9/13 (69.2%) |
Figueiro, et al. [31] |
Y |
N |
U |
N |
Y |
Y |
Y |
Y |
N |
Y |
N |
N |
Y |
7/13 (53.8%) |
Kim, et al. [34] |
Y |
N |
Y |
U |
U |
Y |
U |
Y |
N |
Y |
N |
Y |
Y |
7/13 (53.8%) |
Cibeira, et al. [29] |
U |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
Y |
N |
1/13 (7.69%) |
Hjetland, et al. [32] |
Y |
N |
Y |
N |
Y |
Y |
Y |
Y |
N |
Y |
N |
Y |
Y |
9/13 (69.2%) |
Kolberg, et al. [25] |
Y |
N |
Y |
N |
Y |
Y |
Y |
Y |
N |
Y |
N |
Y |
Y |
10/13 (76.9%) |
Kolberg, et al. [20] |
Y |
N |
Y |
N |
Y |
Y |
Y |
Y |
Y |
Y |
N |
Y |
Y |
9/13 (69.2%) |
Bromundt, et al. [28] |
N |
N |
Y |
N |
N |
N |
N |
Y |
N |
Y |
N |
N |
N |
3/13 (23%) |
Kheradmand, et al. [33] |
Y |
Y |
Y |
U |
U |
Y |
U |
Y |
N |
Y |
U |
N |
Y |
7/13 (53.8%) |
Note: Q1: Randomization; Q2: Concealed allocation; Q3: Groups similar at baseline; Q4: Participants blinded; Q5: Allocator blinded; Q6: Treatment Groups treated equally; Q7: Assessors blinded; Q8: Outcomes measured in the same way in groups; Q9: Outcomes measured reliably; Q10: Follow-up complete; Q11: Participants analysed in original group; Q12: Appropriate statistical analysis; Q13: Appropriate trial design. Abbreviations: Y: Yes; N: No; U: Unclear; N/A: not applicable